Genmab — Januar 2022
-
Genmab A/S (GEN:DC) (GMAB) PT Raised to DKK3,200 at Bernstein https://www.avanza.se/placera/telegram/2022/01/04/genmab-bernstein-hojer-riktkursen-for-genmab-till-3-200-danska-kronor-3-150-upprepar-outperform-bn.html
-
Novo og sundhedsaktier ramt af genåbningshåb vurderer strateg https://www.proinvestor.com/investornyt/758638/novo-og-sundhedsaktier-ramt-af-genabningshab-vurderer-strateg
-
Genmab and Synaffix Enter into License Agreement for ADC Technology
Media ReleaseSynaffix to provide access to proprietary antibody-drug conjugate (ADC) technologies
Genmab secures rights for conducting research on ADCs against multiple drug targets with options for exclusive worldwide development and commercialization of resulting therapies
Synaffix to receive an upfront payment of USD $4.5 million with a total deal value of up to USD $415 million plus tiered single digit royalties on sales -
Genmab and Synaffix Enter into License Agreement for ADC Technology https://www.proinvestor.com/investornyt/758658/genmab-and-synaffix-enter-into-license-agreement-for-adc-technology
-
Synaffix even partnered with ADCT ...
-
https://www.fiercebiotech.com/biotech/415m-line-genmab-taps-synaffix-for-antibody-drug-conjugate-technologies With $415M on the line, Genmab taps Synaffix for antibody-drug conjugate technologies
okHello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind